| Literature DB >> 31078196 |
Teresa Lanza di Scalea1, Teri Pearlstein2.
Abstract
Premenstrual dysphoric disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABAA receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.Entities:
Keywords: Antidepressant; Etiology; Oral contraceptive; Premenstrual dysphoric disorder; Premenstrual syndrome; Treatment
Mesh:
Substances:
Year: 2019 PMID: 31078196 DOI: 10.1016/j.mcna.2019.02.007
Source DB: PubMed Journal: Med Clin North Am ISSN: 0025-7125 Impact factor: 5.456